Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) is advancing a novel approach to cancer therapy that could reshape how certain hard-to-treat tumors are addressed. In a recent appearance on the IBN BioMedWire Podcast, Chief Medical Officer Dr. Islam Mohamed detailed the company's lead drug candidate, ONC010, and its potential to offer a more selective and effective treatment option for patients with cancers characterized by specific genetic deficiencies.
At the heart of Onco-Innovations' strategy is the targeting of polynucleotide kinase phosphatase (PNKP), a DNA repair enzyme that plays a critical role in maintaining genomic integrity. By inhibiting PNKP, ONC010 aims to exploit synthetic lethality—a concept where cancer cells with defects in certain DNA repair pathways become uniquely vulnerable to further disruption of DNA repair mechanisms. Specifically, ONC010 is designed to selectively kill cancer cells that have lost PTEN or SHP-1, two tumor suppressor proteins commonly mutated in various cancers. This selectivity could potentially minimize harm to healthy cells, a major challenge in oncology.
Dr. Mohamed also highlighted the drug's second selectivity mechanism: nanoparticle delivery. This approach is intended to concentrate ONC010 within tumor tissue, enhancing its therapeutic index and reducing systemic exposure. Preclinical research conducted at the University of Alberta demonstrated that the nano-formulated PNKP inhibitor exhibited single-agent antitumor activity, was well-tolerated at tested doses, and significantly prolonged survival compared to controls. These findings provide a strong rationale for advancing ONC010 into human trials.
The company is now preparing for a first-in-human clinical program, a critical milestone that will test the safety and preliminary efficacy of ONC010 in patients. If successful, this could open new avenues for treating cancers that are currently resistant to standard therapies, particularly those with PTEN or SHP-1 deficiencies. The exclusive worldwide license to patented technology directed at PNKP inhibition further solidifies Onco-Innovations' position in this emerging field.
For investors and industry observers, the podcast offers valuable insights into the scientific underpinnings of ONC010 and the company's strategic direction. The full press release can be accessed at https://ibn.fm/XgpMR. Additionally, the latest news and updates relating to ONNVF are available in the company's newsroom at https://ibn.fm/ONNVF.
BioMedWire, the platform that hosted the podcast, is a specialized communications outlet focused on the biotechnology, biomedical sciences, and life sciences sectors. It operates as part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions, article and editorial syndication to over 5,000 outlets, enhanced press release services, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com.
The implications of Onco-Innovations' work extend beyond a single drug candidate. By targeting PNKP, the company is venturing into a relatively unexplored area of DNA damage response, which has already yielded successful therapies like PARP inhibitors. If ONC010 proves effective in clinical trials, it could provide a new treatment option for patients with limited alternatives and validate PNKP as a viable clinical target. This would not only benefit Onco-Innovations but also spur further research into synthetic lethality and nanoparticle delivery in oncology.
As the company moves toward first-in-human studies, the oncology community will be watching closely. The outcomes of these trials will determine whether ONC010 can fulfill its promise and whether Onco-Innovations can establish itself as a key player in the next generation of cancer therapeutics.
